Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preservative-free travoprost versus TRAVATAN in open-angle glaucoma or ocular hypertension
2014-002576-91Phase 3Completed
- Sponsor
- OmniVision
- Start
- Aug 2014
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of travoprost in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by OmniVision. Primary endpoint: Average diurnal intraocular pressure change from baseline to end of follow-up. Started Aug 2014; status: completed.
02
Drugs
travoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2014-002576-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002576-91.